HEPATOLOGY WATCH®
Timely
Information for Practicing Physicians
SPECIAL
ISSUE: HIGHLIGHTS OF ROCHE SATELLITE SYMPOSIA
OCTOBER
19, 2001 acg ANNUAL MEETING: PROGRESS
IN THE MANAGEMENT OF HEPATITIS C
NOVEMBER
12, 2001 AASLD ANNUAL MEETING:
PEGYLATED INTERFERONS IN HCV – TREATMENT OUTCOMES
GOALS OF
THERAPY IN PATIENTS WITH HEPATITIS C: Dr. Raymond Koff reviewed recent evidence that treatment
with interferon (IFN) alfa-2b (5 MU daily x 4 wk and then tiw x 20 wk) resulted
in an SVR in 98% (43/44) of patients with acute hepatitis C and thus
definitively achieves the goal of decreasing the risk of chronicity following
acute infection (Jaeckel et al. N Engl J Med 2001;345:1452). In patients
with chronic hepatitis C, eradication of HCV and cessation of disease
progression can be achieved overall in approximately 55% of naïve patients
treated with peginterferon (PEG IFN) alfa-2a or alfa-2b plus ribavirin. In
relapsers to prior antiviral therapy, HCV eradication can be achieved in a
smaller percentage of patients. In nonresponders, rates of HCV eradication with
retreatment are low and a new strategy under study is HCV suppression with
interruption of progression to fibrosis.
PHARMACOLOGY OF PEGYLATION:
Dr.Thomas Shaw-Stiffel reviewed pharmacokinetic (PK) profiles associated with
the attachment of polyethylene glycol (PEG) to IFN and differences between PEG
IFN alfa-2a and PEG IFN alfa-2b. Standard IFN has a very short half-life (6
hr), wide distribution throughout the body, and rapid clearance by the kidneys.
PEG IFN alfa-2a results from the strong, covalent attachment of a 40-kDa
branched PEG to IFN alfa-2a. At a dosage of 180 mg once weekly (qw), a steady state is reached at 5-8 wk;
volume of distribution approaches total blood volume; and clearance is
primarily by the liver. PEG INF alfa-2b results from the weak, noncovalent
attachment of a 12-kDa linear PEG to IFN alfa-2b, and renal elimination
accounts for 30% of the clearance. For PEG IFN alfa-2a, PK properties are
unchanged in patients with renal impairment down to a Cr clearance of 20
mL/min, but some dose adjustment is needed with PEG IFN alfa-2b below a Cr
clearance of 50 mL/min. There are no differences in the PK properties of PEG
IFN alfa-2a and alfa-2b between men and women, and PK profiles are unchanged in
the elderly. PEG IFN alfa-2a has been extensively studied in patients with
cirrhosis, and the PK and pharmacodynamic (PD) properties are unchanged in
Child’s A cirrhosis. The different PK and PD profiles, especially volume of
distribution, result in different dosing regimens for the two PEG compounds:
PEG IFN alfa-2a is dispensed as a stable solution and can be administered at a
uniform dose of 180 mg, while PEG INF alfa-2b is dispensed as a lyophilized
powder that needs to be reconstituted before injection and must be dosed by
weight.
MONOTHERAPY AND VIRAL KINETICS
WITH PEGYLATED INTERFERON: Dr. Mitchell Schiffman reviewed the results of PEG IFN
monotherapy in patients with chronic hepatitis C. In a phase III multinational
study of 531 treatment-naïve patients with chronic hepatitis C, patients were
randomized to IFN alfa-2a 6 MU tiw x 12 wk and then 3 MU x 36 wk vs PEG IFN
alfa-2a 180 mg
qw for 48 wk (Zeuzem et al. N Engl J Med 2000;343:1666). The SVR was 19%
vs 39% for the two treatment arms, respectively. In a similar study of PEG INF
alfa-2b, 1219 patients were randomized to 48 wk of IFN alfa-2b 3 MU tiw or PEG
IFN alfa-2b qw at doses of 0.5 mg/kg, 1.0 mg/kg qw, or 1.5 mg/kg (Lindsay et al. Hepatology 2001;34:395). The SVR
was 12%, 18%, 25%, and 23%, respectively. Thus, although overall response rates
varied, both PEG IFN alfa-2a and alfa-2b were approximately twice as effective
as respective standard IFN products in inducing an SVR. Dr. Stefan Zeuzem
reviewed viral kinetics and treatment outcomes. In an intent-to-treat analysis
of 564 patients receiving PEG IFN alfa-2a, patients who did not clear virus or
have at least a 2-log10 drop in viral load from baseline at wk 12 of
therapy had a 98% chance of nonresponse. The study of combination PEG IFN
alfa-2a and ribavirin also showed that the lack of an early response at wk 12
is highly predictive of eventual nonresponse (negative predictive response =
97%) (Fried et al. Gastroenterology 2001;120:A-55). In the Fried trial,
the overall SVR was 56%; in those patients with a viral response at wk 12, the
SVR was 65%.
COMBINATION THERAPY WITH
PEGINTERFERON AND RIBAVIRIN: Drs. Luis Balart and Morris Sherman reviewed the
intention-to-treat results of combination therapy with PEG IFN and ribavirin in
patients with chronic hepatitis C. Studies using PEG IFN alfa-2a 180 mg plus ribavirin
1000-1200 mg/d (Fried et al. Gastronterology 2001;120:A-55) and PEG IFN
alfa-2b with the 1.5 mg/kg dose plus ribavirin 800 mg/d (Manns et al. Lancet
2001;358:958) showed the following SVR, respectively: 56% vs 54% overall; 46% vs 42% in patients with genotype 1; and 75% vs
82% in patients with genotypes 2 and 3. In the PEG IFN alfa-2a pivotal study,
several adverse events (including flu-like symptoms and depression) occurred
less frequently with PEG IFN alfa-2a in combination with ribavirin compared
with standard IFN alfa-2b plus ribavirin. Comparison of safety and tolerability
between the two PEG IFN products is difficult, but injection side effects,
depression, and flu-like symptoms may be more common with PEG INF alfa-2b.
Rates of withdrawal in the two studies were 10.5% for PEG IFN alfa-2a vs 14%
for PEG IFN alfa-2b.
HISTOLOGIC OUTCOMES AND SPECIAL
POPULATIONS: Dr. Russell Wiesner reviewed published data demonstrating
that IFN-based therapies decrease both necroinflammatory and fibrosis scores,
particularly in patients with a SVR, and even show reversal of cirrhosis in a
relatively large number of successfully treated patients (Poynard et al. Hepatology
2001;34:244A). However, nonresponders also show a decrease in fibrosis
formation, raising the potential benefit of long-term IFN therapy – presently
being addressed by the Halt-C study sponsored by the National Institutes of
Health. African Americans have been shown to be unresponsive to IFN monotherapy,
but PEG IFN alfa-2a and alfa-2b achieve a SVR of 15% and 14%. Finally, PEG IFN
plus ribavirin may achieve an SVR in up to 36% of patients with recurrent HCV
posttransplant (Ferenci et al. Hepatology 2001;34:351A).
Hepatology Watch is produced through educational grants from
and 
Hepatology Watch is a registered trademark of Market Development Group